Celldex Therapeutics Inc (CLDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.25B
Last updated: Nov 17, 2026 at 4:15 PM ET
Celldex Therapeutics Inc (CLDX) Stock Chart
Celldex Therapeutics (CLDX) has a latest price of $28.04 on Nov 17, 2026, 37.9% below its 52-week high of $45.14. Its price rose 9.7% over the past 12 months. The month-end price fell 36.3% over the 10 years through Oct 2026, a compound annual decline of 4.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $57.12 in Nov 2016 and its lowest $1.66 in Mar 2020, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CLDX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CLDX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 32.8%, and over 6 months it fell 7.0%. The month-end price rose 28.0% over the 3 years through Oct 2026, a compound annual rate of 8.6%.
| Period | Change |
|---|---|
| 1 month | -5.5% |
| 3 months | -32.8% |
| 6 months | -7.0% |
| 12 months | +9.7% |
| 12 months, with dividends | +9.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +28.0% | +8.6% |
| 5 years | -29.2% | -6.7% |
| 10 years | -36.3% | -4.4% |
Price by Year
Its best calendar year was 2020, when the price rose 685.7%, and its weakest was 2018, when it fell 93.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $30.10 | +10.8% |
| 2025 | $27.16 | +7.5% |
| 2024 | $25.27 | -36.3% |
| 2023 | $39.66 | -11.0% |
| 2022 | $44.57 | +15.3% |
| 2021 | $38.64 | +120.5% |
| 2020 | $17.52 | +685.7% |
| 2019 | $2.23 | -24.8% |
| 2018 | $2.97 | -93.0% |
| 2017 | $42.58 | -19.8% |
Trading Range
The price is 11.1% below its 50-day average of $31.54 and 14.7% below its 200-day average of $32.88.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $28.04 | |
| 52-week high | $45.14 | -37.9% |
| 52-week low | $22.33 | +25.6% |
| 50-day average | $31.54 | -11.1% |
| 200-day average | $32.88 | -14.7% |
Price Risk
Over 3 years, its largest fall from a peak was 70.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.22 |
| Largest fall, 1 year | -38.6% |
| Largest fall, 3 years | -70.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CLDX
What is CLDX's 1-year price change?
Celldex Therapeutics's price rose 9.7% over the past 12 months. With dividends included, the 12-month total return was 9.7%.
What is CLDX's 5-year price change?
Celldex Therapeutics's month-end price fell 29.2% over the 5 years through Oct 2026, a compound annual decline of 6.7%. These figures leave out dividends.
What is CLDX's 52-week high and low?
Celldex Therapeutics's 52-week high is $45.14 and its 52-week low is $22.33. Its latest price of $28.04 on Nov 17, 2026 is 37.9% below the high.
What is CLDX's beta?
Celldex Therapeutics's 1-year beta against the S&P 500 is 1.22, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 38.6%.
Is the CLDX chart free?
Yes. Advanced Charting for CLDX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CLDX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors